Anixa Biosciences, Inc. ANIX
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.17% | -17.37% | -12.00% | 2.79% | -17.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.36% | -11.85% | -19.79% | -9.07% | -32.18% |
| Operating Income | -12.36% | 11.85% | 19.79% | 9.07% | 32.18% |
| Income Before Tax | -15.13% | 9.85% | 19.55% | 6.56% | 31.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.13% | 9.85% | 19.55% | 6.56% | 31.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -13.64% | -13.04% | -31.03% | -10.00% | -42.11% |
| Net Income | -15.41% | 9.82% | 19.44% | 6.52% | 31.10% |
| EBIT | -12.36% | 11.85% | 19.79% | 9.07% | 32.18% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -9.64% | 13.51% | 21.94% | 8.71% | 32.00% |
| Normalized Basic EPS | -9.72% | 13.54% | 21.95% | 8.63% | 31.97% |
| EPS Diluted | -9.64% | 13.51% | 21.94% | 8.71% | 32.00% |
| Normalized Diluted EPS | -9.72% | 13.54% | 21.95% | 8.63% | 31.97% |
| Average Basic Shares Outstanding | 5.25% | 4.32% | 3.24% | 2.35% | 1.32% |
| Average Diluted Shares Outstanding | 5.25% | 4.32% | 3.24% | 2.35% | 1.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |